April 16, 2018 / 5:53 AM / 5 months ago

BRIEF-Lysogene Had Cash And Cash Equivalent Of EUR 9.9 Million On March 31

April 16 (Reuters) - LYSOGENE SA:

* LYSOGENE REPORTS FIRST QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENT AMOUNTED TO EUR 9.9 MILLION

* LYSOGENE DID NOT GENERATE REVENUES DURING Q1 2018

* LYS-SAF302 IN MPS IIIA: PIVOTAL CLINICAL TRIAL NOW SCHEDULED TO START IN H2 OF 2018

* LYS-GM101 IND-ENABLING PRECLINICAL STUDY PROGRAM IN GM1: INTENDS TO REPORT LONG-TERM RESULTS IN H2 OF 2018 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below